Thyroid transcription factor 1 (TTF‐1) negativity as a predictor of unfavorable response to EGFR‐TKI therapy in advanced lung adenocarcinoma patients with EGFR mutations
Abstract Background The absence of thyroid transcription factor 1 (TTF‐1) is associated with a lower frequency of epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma (LUAD). The aim of this study was to assess the impact of TTF‐1 expression on the clinical response to EGFR‐tyros...
Main Authors: | Xiaosheng Ding, Weiwei Shi, Bingxuan Han, Hanxiao Chen, Jia Li, Juan An, Lili Zhou, Weiran Xu, Hui Shi, Xixi Zheng, Yichun Hua, Xiaoyan Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-10-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.15079 |
Similar Items
-
Advances in the Research of Autophagy in EGFR-TKI Treatment and Resistance
in Lung Cancer
by: Qicheng ZHANG, et al.
Published: (2016-09-01) -
Targeting HER3 to overcome EGFR TKI resistance in NSCLC
by: Qiuqiang Chen, et al.
Published: (2024-01-01) -
Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an <i>EGFR</i>-Activating Mutation
by: Shigetoshi Nishihara, et al.
Published: (2022-07-01) -
Chemotherapy outcomes in EGFR‐TKI resistant patients with common and uncommon EGFR mutation: An exploratory retrospective cohort study
by: Chien‐Yu Lin, et al.
Published: (2023-07-01) -
Local Treatment Combined with EGFR-TKIs for Advanced Non-small Cell Lung Cancer with Solitary Progression during EGFR-TKI Treatment
by: Xin ZHANG, et al.
Published: (2013-10-01)